Anti-human epidermal growth factor receptor 2 (HER2) treatments have been integrated very successfully into the treatment of patients with HER2-positive breast cancer (BC), since the discovery that HER2 amplifications have a major impact on the prognosis in BC patients [1]. Here, ERBB2 is linked to breast carcinoma.